Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234935 · ClinicalTrials.gov registry record · Phase 2
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01234935 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 8 participants.
The verdict
NCT01234935, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving dasatinib together with gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating pancreatic cancer. PURPOSE: This randomized phase II trial is studying how well giving dasatinib together with gemcitabine hydrochloride works compared to giving gemcitabine hydrochloride alone in treating patients with pancreatic cancer previously treated with surgery.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC mutation analysis
- DRUG dasatinib
- DRUG gemcitabine hydrochloride
- GENETIC nucleic acid sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-01-13 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234935
The ClinicalTrials.gov registry entry for NCT01234935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01234935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234935 about?
NCT01234935 is a clinical study titled "Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It i...
What is the current status of trial NCT01234935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-01-13. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT01234935?
The interventions under investigation include: laboratory biomarker analysis (OTHER), mutation analysis (GENETIC), dasatinib (DRUG), gemcitabine hydrochloride (DRUG), nucleic acid sequencing (GENETIC).
Who is sponsoring clinical trial NCT01234935?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.